The HLA crossroad in tumor immunology

Human Immunology

Volumn 61, Issue 1, 2000, Pages 65-73

  Algarra, Ignacio ^a   Cabrera, Teresa ^b   Garrido, Federico ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

Author keywords

Escape; Expression; HLA; Phenotypes; Tumors

Indexed keywords

HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; HLA SYSTEM; IMMUNE RESPONSE; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 0033972180     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00156-1     Document Type: Article

References (41)

1. Gorer P.A. The detection of antigenic differences in mouse erythrocytes by the employment of immune sera. Br J Exp Pathol. 17:1936;42.
2. Snell G.D. Enhancement and inhibition of the growth of tumor homotransplants by pretreatment of the hosts with various preparations of normal and tumor tissue. J Natl Cancer Inst. 13:1952;719.
3. Klein G., Sjögren H., Klein E., Hellström K.E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochtonous host. Cancer Res. 20:1960;1561.
4. Townsend A., Rothbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 44:1986;959.
5. Boon T. Antigenic tumor cell variants obtained with mutagens. Adv Cancer Res. 39:1983;121.
6. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay Y.J. The host tumor immune conflict from immunosuppression to resistance and destruction. Immunol Today. 18:1997;493.
7. Garrido F., Cabrera T., Concha A., Glew S., Ruiz-Cabello F., Stern P.L. Natural history of HLA expression during tumour development. Immunol Today. 14:1993;491.
8. Hicklin D.J., Marincola F.M., Ferrone S. HLA class I antigen downregulation in human cancers T-cell immunotherapy revives an old story . Mol Med Today. 5:1999;178.
9. Festenstein H. The biological consequences of altered MHC expression on tumours. Br Med Bull. 43:1987;217.
10. Garrido F., Klein E. MHC antigen expression. I. Human tumors. Semin Cancer Biol. 2:1991;1.
11. Festenstein H., Schmidt W. Variation in MHC antigenic profiles of tumor cells and its biological effects. Immunol Rev. 60:1981;85.
12. Garrido F., Festenstein H., Schirrmacher V. Further evidence for derepression of H-2 and Ia like specificities of foreign haplotypes in mouse tumour cell lines. Nature. 261:1976;705.
13. d sarcoma. J Immunogenet. 6:1979;83.
14. Smith M.E.F., Marsh S.G.E., Bodmer J.G., Gelsthorpe K., Bodmer W.F. Loss of HLA A, B, C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci USA. 86:1989;5557.
15. Kaklamanis L., Hill A. MHC loss in colorectal tumours evidence for immunoselection? Cancer Sur. 13:1992;155.
16. Moretta A., Bottino C., Vitale M., Pende D., Biassoni R., Mingari M.C., Moretta L. Receptors for HLA class I molecules in human natural killer cells. Ann Rev Immunol. 14:1996;619.
17. Gutierrez J., López-Nevot M.A., Cabrera T., Oliva R., Esquivias F., Ruiz-Cabello F., Garrido F. Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma relation with malignancy and invasiveness . Exp Clin Immunogenet. 4:1987;144.
18. Garrido F., Cabrera T., Accolla R.S., Bensa J.C., Bodmer W., Dohr G., Drenou B., Drouet M., Fauchet R., Ferrara G.B., Ferrone S., Giacomini P., Kageshita T., Koopman L., Maio M., Marincola F., Mazzilli C., Morel P.A., Murray A., Papasteriades C., Salvaneschi L., Stern P.L., Ziegler A. HLA and Cancer. Charron D. Genetic Diversity of HLA Functional and Medical Implication. Vol. I:1997;445 EDK, Paris.
19. Garrido F., Ruiz-Cabello F., Cabrera T., Pérez-Villar J., López-Botet M., Duggan-Keen M., Stern P.L. Implications for immunosurveillance of altered class I phenotypes in human tumours. Immunol Today. 18:1997;89.
20. Ruiz-Cabello F., Garrido F. HLA and cancer from research to clinical impact . Immunol Today. 19:1998;539.
21. 2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens. 52:1998;520.
22. 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens. 53:1999;1.
23. Browning M., Petronzelli F., Bicknell D., Kraus P., Rowan A., Tonks S., Murray N., Bodmer J., Bodmer W. Mechanism of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens. 47:1996;364.
24. 2 m gene expression. J Clin Invest. 87:1991;284.
25. Blanchet O., Bourge J.F., Zinszner H., Tatari Z., Degos L., Paul P. DNA binding of regulatory factor interacting with MHC-class I gene enhancer correlates with MHC class I transcriptional level in class I defective cell lines. In J Cancer. 6:1991;138.
26. Cromme F.V., Airey J., Heemels M.T., Ploegh H.L., Keating P.J., Stern P.L., Meijer C.J.L.M., Walboomers J.M.M. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med. 179:1994;335.
27. Torres M.J., Ruiz-Cabello F., Skoudy A., Berrozpe G., Jimenez P., Serrano A., Real F.X., Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens. 47:1996;372.
28. Algarra I., Collado A., Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res. 27:1997;95.
29. Amiot L., Onno M., Lamy T., Dauriac C., Le Prise P.Y., Fauchet R., Drenau B. Loss of HLA molecules in B lymphomas is associated with an aggressive behaviour. Brit J Haematol. 100:1998;655.
30. Garrido F. HLA and Cancer. Tissue Antigens. 47:1996;361.
31. Jimenez P., Cantón J., Collado A., Cabrera T., Serrano A., Real A., Garcia A., Ruiz-Cabello F., Garrido F. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer. 83:1999;91.
32. Real L.M., Jimenez P., Cantón J., Kirkin A., Garcia A., Abril E., Zeuthen J., Ruiz-Cabello F., Garrido F. In vivo and in vitro generation of a new altered HLA phenotype in melanoma tumor cell variants expressing a single HLA class I allele. Int J Cancer. 75:1998;317.
33. Cabrera T., Fernandez M.A., Sierra A., Garrido A., Herruzo A., Escobedo A., Fabra A., Garrido F. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol. 50:1996;127.
34. Cabrera T., Collado A., Fernandez M.A., Ferrón A., Sancho J., Ruiz-Cabello F., Garrido F. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens. 52:1998;114.
35. Lehmann F., Marchand M., Hainaut P., Sastre X., Ikeda H., Boon T., Coulie P.G. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol. 25:1995;340.
36. Ikeda H., Lethé B., Lehmann F., Van Baren N., Baurain J.F., De Smet C., Chambost H., Vitale M., Moretta A., Boon T., Coulie P.G. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expression an NK inhibitory receptor. Immunity. 6:1997;199.
37. Tolimson I., Bodmer W. Selection, the mutation rate and cancer ensuring that the tail does not wag the dog . Nat Med. 5:1999;11.
38. Paul P., Rouas-Freis N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., Avril M.F., Dausset J., Guillet J.G., Carosella E. HLA G expression in melanomas a way for tumor cells to escape from immunosurveillance . Proc Nat Acad Sci USA. 95:1998;4510.
39. Le Boutellier P. HLA-G the track of immunological function . Eur J Immunogenet. 24:1997;397.
40. Real L.-M., Cabrera T., Collado A., Jimenez P., Garcia A., Ruiz-Cabello F., Garrido F. Expression of HLA-G in human tumors is not a frequent event. Int J Cancer. 81:1999;512.
41. Marchand M., Von Baren N., Weynants P., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:1999;219.